Journal
CARDIOVASCULAR THERAPEUTICS
Volume 31, Issue 3, Pages 125-137Publisher
WILEY
DOI: 10.1111/j.1755-5922.2011.00310.x
Keywords
Cardiovascular disease; NADPH oxidase; new therapeutics; aptamers
Funding
- BLRD VA [I01 BX001729] Funding Source: Medline
- VA [732740, 5I01BX001729-04] Funding Source: Federal RePORTER
Ask authors/readers for more resources
Over 40 years ago, NADPH (nicotinamide adenine dinucleotide phosphate) oxidase 2 (Nox2) was discovered in phagocytes and found to be essential in innate immunity. More than 20 years passed before additional Nox isoforms were discovered; and since then, studies have revealed that several of these isoforms (Nox1, Nox2, Nox4, and Nox5) are found in human cardiac and vascular cells and contribute to the pathogenesis of cardiovascular diseases (CVDs). Recently, major efforts have focused on identifying inhibitors capable of ameliorating Nox-mediated CVD. In this review, we briefly discuss the role of each Nox isoform in CVD, identify steps in Nox signaling that will serve as potential targets for the design of therapeutics, and highlight innovative strategies likely to yield effective Nox inhibitors within the next decade.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available